Suppr超能文献

口服髓鞘碱性蛋白对实验性自身免疫性脑脊髓炎的抑制作用。VI. 对过继转移疾病的抑制以及口服与静脉耐受的不同效果。

Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization.

作者信息

Miller A, Zhang Z J, Sobel R A, al-Sabbagh A, Weiner H L

机构信息

Department of Medicine, Brigham and Women's Hospital, Boston, MA.

出版信息

J Neuroimmunol. 1993 Jul;46(1-2):73-82. doi: 10.1016/0165-5728(93)90235-q.

Abstract

Antigen-driven tolerance is an effective method of suppressing cell-mediated immune responses. We have previously shown that oral administration of myelin basic protein (MBP) suppresses experimental autoimmune encephalomyelitis (EAE) when it is actively induced by MBP emulsified in complete Freund's adjuvant. In order to further study antigen-driven tolerance in this model, we investigated the effect of oral tolerization on adoptively transferred EAE and compared oral tolerance to intravenously (i.v.) administered MBP in both actively induced EAE and adoptively transferred EAE. Although orally tolerized animals were not protected from adoptively transferred EAE, spleen cells from orally tolerized animals suppressed adoptively transferred EAE when co-transferred with encephalitogenic cells or when injected into recipient animals at a different site at the time encephalitogenic cells were transferred. This suppression was mediated by CD8+ T cells, correlated with suppression of DTH responses to MBP, and was associated with decreased inflammation in the spinal cord. Unlike oral tolerization, spleen cells from i.v. tolerized animals did not suppress adoptively transferred EAE when co-transferred with encephalitogenic cells although i.v. tolerized animals were protected from adoptively transferred EAE. MBP peptides were then utilized to further characterize differences between i.v. and oral tolerization in the actively induced disease model. Both orally and intravenously administered MBP suppressed actively induced EAE. However, EAE was only suppressed by prior i.v. tolerization with the encephalitogenic MBP peptide 71-90, but not with the non-encephalitogenic peptide 21-40, whereas prior tolerization with 21-40 did suppress actively induced EAE when administered orally. These results suggest a different mechanism of tolerance is initiated by oral vs. intravenous administered antigen. Specifically, oral tolerization suppresses primarily by the generation of active suppression whereas the dominant mechanism of suppression associated with i.v. tolerization appears most consistent with the elicitation of clonal anergy.

摘要

抗原驱动的耐受是抑制细胞介导免疫反应的一种有效方法。我们之前已经表明,口服髓鞘碱性蛋白(MBP)可抑制实验性自身免疫性脑脊髓炎(EAE),前提是EAE由完全弗氏佐剂乳化的MBP主动诱导产生。为了在该模型中进一步研究抗原驱动的耐受,我们调查了口服耐受对过继转移EAE的影响,并在主动诱导的EAE和过继转移的EAE中比较了口服耐受与静脉注射(i.v.)MBP的效果。尽管口服耐受的动物未免受过继转移EAE的影响,但口服耐受动物的脾细胞在与致脑炎性细胞共同转移时,或在致脑炎性细胞转移时于不同部位注射到受体动物体内时,可抑制过继转移的EAE。这种抑制由CD8 + T细胞介导,与对MBP的迟发型超敏反应(DTH)的抑制相关,并与脊髓炎症减轻有关。与口服耐受不同,静脉注射耐受动物的脾细胞在与致脑炎性细胞共同转移时不抑制过继转移的EAE,尽管静脉注射耐受的动物免受了过继转移EAE的影响。然后利用MBP肽进一步表征主动诱导疾病模型中静脉注射和口服耐受之间的差异。口服和静脉注射的MBP均抑制主动诱导的EAE。然而,只有预先静脉注射致脑炎性MBP肽71 - 90可抑制EAE,而预先注射非致脑炎性肽21 - 40则不能,而预先口服21 - 40在给药时确实可抑制主动诱导的EAE。这些结果表明,口服与静脉注射抗原引发的耐受机制不同。具体而言,口服耐受主要通过产生主动抑制来抑制,而与静脉注射耐受相关的主要抑制机制似乎最符合克隆无能的引发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验